A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

Condition:   Multiple Myeloma Interventions:   Biological: bb2121 carfilzomib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Lenalidomide Sponsor:   Celgene Not yet recruiting

Source: ClinicalTrials.gov - December 12, 2019 Category: Research Source Type: clinical trials